Welcome to our dedicated page for Acrivon Therapeutics SEC filings (Ticker: ACRV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Acrivon Therapeutics, Inc.’s SEC filings document the formal disclosures of a Nasdaq-listed clinical-stage biotechnology company focused on precision oncology. Its 8-K reports cover results of operations, financial condition, Regulation FD presentations, pipeline updates for ACR-368 and ACR-2316, and disclosures related to its internal CLIA-certified laboratory and companion diagnostic activities.
The company’s proxy materials describe annual meeting matters, board elections, auditor ratification, executive and director governance, and stockholder voting procedures. Filing records also identify the company’s common stock registration on Nasdaq and provide exhibits that support business updates, clinical program presentations, material agreements, and risk-related public-company reporting.
Acrivon Therapeutics, Inc. reported that Chief Operating Officer Eric Devroe had 613 shares of Common Stock withheld on May 14, 2026 to cover mandatory tax obligations tied to the vesting of restricted stock units. The shares were valued at $1.92 per share for this tax-withholding disposition, which is an administrative mechanism rather than an open-market sale. Following this event, Devroe holds 73,972 Common Stock shares directly, indicating he retains essentially his full equity position while satisfying the required tax liability.
Acrivon Therapeutics executives reported routine tax-related share dispositions tied to restricted stock unit vesting. A total of 1,743 common shares at $1.92 were withheld by the company to satisfy mandatory tax obligations, rather than sold in the open market.
After these withholdings, one executive directly holds 2,078,951 shares and another has 313,637 shares reported as indirectly held through spousal ownership, reflecting that both retain substantial positions following the transactions.
Citadel reporting persons jointly disclose beneficial ownership of 13 shares of Acrivon Therapeutics common stock. The filing states Citadel Securities LLC and affiliated entities may be deemed to beneficially own 13 shares, constituting 0.0% of the class. The filing cites 38,744,446 Shares outstanding as of March 16, 2026 as the basis for the percentage.
The statement is a joint Schedule 13G/A signed by authorized signatories and includes attribution of shared voting and dispositive power for the 13 shares to Citadel Securities and related entities.
Acrivon Therapeutics reported a net loss of $19.0 million for the quarter ended March 31, 2026, slightly improved from $19.7 million a year earlier. Research and development expenses were $15.2 million, reflecting continued investment in lead programs ACR-368 and ACR-2316, while general and administrative costs declined to $4.7 million as stock-based compensation decreased.
Cash, cash equivalents and investments totaled $97.7 million at quarter-end, and the company subsequently raised an additional $7.3 million through its at-the-market equity program. Management believes this liquidity will fund operations into the third quarter of 2027 as it advances its precision oncology pipeline, including a registrational-intent Phase 2b trial of ACR-368 in endometrial cancer and a Phase 1/2 trial of WEE1/PKMYT1 inhibitor ACR-2316.
Acrivon Therapeutics reported first quarter 2026 results and highlighted progress across its oncology pipeline. Net loss was $19.0 million versus $19.7 million a year earlier, with research and development expenses of $15.2 million and general and administrative expenses of $4.7 million, reflecting lower employee-related costs.
Cash, cash equivalents and investments totaled $97.7 million as of March 31, 2026, and together with $7.3 million from a subsequent equity financing are expected to fund operations into the third quarter of 2027. Clinically, the registrational intent Phase 2b trial of ACR-368 in endometrial cancer showed a confirmed overall response rate of 52% in serous patients compared with 22% in non-serous patients, with an interim analysis of serous arms planned for the second half of 2026. The ACR-2316 Phase 1/2 study is moving toward expansion after early signs of durable activity and a mainly transient neutropenia safety profile, including responses in heavily pretreated lung cancers.
Acrivon Therapeutics, Inc. is holding its 2026 Annual Meeting of Stockholders on June 17, 2026 at 1:00 PM Eastern Time as a virtual-only event at https://www.proxypush.com/ACRV, for holders of record as of April 23, 2026.
Stockholders are asked to elect two Class I directors, Michael Tomsicek and Charles Baum, each for a three-year term ending at the 2029 annual meeting, and to ratify the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. The Board recommends a vote “FOR” all nominees and “FOR” auditor ratification and describes its governance structure, committee composition, director independence, and executive compensation, including 2025 salaries, bonuses and equity awards for senior management.
RA Capital Management and related parties report owning 12,284,906 shares of Acrivon Therapeutics, or 28.8% of the common stock. This follows the RA Capital Healthcare Fund’s purchase of 3,888,888 shares in an at-the-market offering at $1.80 per share for $6,999,998.40 in cash.
The ownership includes 11,803,094 shares held by the Fund, 426,302 shares held by RA Capital Nexus Fund II, L.P., and 55,510 vested stock options held by Dr. DiRocco for the benefit of RA Capital. The ownership percentages are based on 38,744,446 shares outstanding as of March 16, 2026 plus the new ATM shares and exercisable options.
Acrivon Therapeutics, Inc. reported that investment entities affiliated with RA Capital acquired additional common stock through a grant or similar award. On the reported date, these entities indirectly obtained 3,888,888 shares of common stock at $1.80 per share, bringing one aggregated indirect position to 11,803,094 shares following the transaction. Another indirect holding line shows 426,302 shares after the same date. The filing notes that RA Capital Management, L.P., its general partner, and individuals Peter Kolchinsky and Rajeev Shah disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest.
Acrivon Therapeutics, Inc. Chief Legal Officer Mary Miller reported a routine tax-related share disposition. On the vesting of restricted stock units, 558 shares of common stock were withheld by the company at $1.78 per share to satisfy mandatory tax withholding obligations.
After this withholding, Miller directly holds 33,121 shares of Acrivon common stock. The filing shows no open-market purchases or sales, only this non-discretionary tax-withholding event tied to equity compensation.